A three-year longitudinal evaluation of the forearm bone density of users of etonogestrel- and levonorgestrel-releasing contraceptive implants

نویسندگان

  • Cecilia Monteiro-Dantas
  • Ximena Espejo-Arce
  • Jeffrey F Lui-Filho
  • Arlete M Fernandes
  • Ilza Monteiro
  • Luis Bahamondes
چکیده

BACKGROUND The aim of this study was to evaluate bone mineral density (BMD) at baseline and at 18 and 36 months of use of etonogestrel (ENG)-and levonorgestrel (LNG)-releasing contraceptive implants. This is a continuation of a previous study in which BMD was evaluated at baseline and at 18 months of use. METHODS A total of 111 women, 19-43 years of age, were randomly allocated to use one of the two implants. At 36 months of follow-up, only 36 and 39 women were still using the ENG- and LNG-releasing implants, respectively. BMD was evaluated at the distal and at the ultra-distal radius of the non-dominant forearm using dual-energy X-ray absorptiometry. RESULTS There was no difference in the BMD of users of either implant at 18 and at 36 months. BMD was significantly lower at 18 and at 36 months at the distal radius in both groups of users compared to pre-insertion values; however, no difference was found at the ultra-distal radius. CONCLUSION Women 19-43 years of age using either one of these two contraceptive implants for 36 months had lower BMD values at the distal radius compared to pre-insertion values; however, no difference was found at the ultra-distal radius.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

A prospective study of the forearm bone density of users of etonorgestrel- and levonorgestrel-releasing contraceptive implants.

BACKGROUND The aim of the study was to compare bone mineral density (BMD) before insertion and at 18 months of use of etonorgestrel- and levonorgestrel-releasing contraceptive implants. METHODS One hundred and eleven women, 19-43 years of age, were randomly allocated to two groups: 56 to etonorgestrel and 55 to levonorgestrel. BMD was evaluated at the midshaft of the ulna and at the distal ra...

متن کامل

Extended Effectiveness of the Etonogestrel-Releasing Contraceptive Implant and the 20 µg Levonorgestrel-Releasing Intrauterine System for 2 Years Beyond U.S. Food and Drug Administration Product Labeling

BACKGROUND Contraceptive implants, the levonorgestrel-releasing intrauterine system (LNG IUS), and the copperbearing intrauterine device (IUD) are long-acting reversible contraceptives (LARCs) with high contraceptive effectiveness. The cumulative pregnancy rates in the first 3 years of use of LARCs is 0.9 per 100 woman-years. In comparison, the percentages of women experiencing an unintended pr...

متن کامل

Avoiding controversy in international provision of subdermal contraceptive implants.

International agencies work with host country governments to estimate contraceptive needs and to procure commodities at affordable public-sector prices. Depending on the agency and the registration status of the commodity in the given country, three subdermal contraceptive implants are options for purchase: Jadelle® is a two-rod levonorgestrel implant approved for 5 years of continuous use (Bay...

متن کامل

A 2-year comparative study of endometrial histology and cervical cytology of contraceptive implant users in Birmingham, UK.

The objectives of this study were to evaluate the endometrial histology and cervical cytology of users of two contraceptive implants releasing etonogestrel/3-keto-desogestrel (Implanon) and levonorgestrel (Norplant) in West Midlands (UK) users. A 2-year prospective randomized design was used to study 60 implant users. Endometrial histology and cervical cytology were compared before insertion an...

متن کامل

Methods of accurate localisation of non-palpable subdermal contraceptive implants.

©FSRH J Fam Plann Reprod Health Care 2008: 34(1) Introduction Implanon® (Organon International, Oss, The Netherlands) is a single rod, subdermal contraceptive implant system designed to release the progestogen etonogestrel at a near constant rate over 3 years.1,2 This system entered the market in The Netherlands in 1998, and soon after in many other countries in Europe and Asia. It is now marke...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Reproductive Health

دوره 4  شماره 

صفحات  -

تاریخ انتشار 2007